IDN 5390

IDN 5390 is a novel C-seco taxane derivative developed by Indena S.p.A. Unlike traditional cytotoxic taxanes such as paclitaxel, IDN 5390 was specifically selected for its potent antimotility activity and low cytotoxicity toward endothelial cells, highlighting its potential as an antiangiogenic agent. It functions by targeting tubulin, but its biological profile is more cytostatic than cytotoxic, making it suitable for prolonged treatment regimens. Preclinical studies demonstrated significant efficacy in various human tumor xenografts, including ovarian cancer, colon cancer, and glioblastoma, even in models resistant to paclitaxel. The compound exhibits high oral bioavailability and can also be administered subcutaneously. While it received FDA approval for Phase I clinical trials in the early 2000s, development appears to have stalled, with no evidence of progression to later-stage clinical testing.

Other names

13-(N-Boc-beta-isobutylisoserinyl)-10beta-dehydro-C-seco-10-deacetylbaccatin IIIC-seco taxane